SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Changes in the balances of intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
Sep. 30, 2021	Sep. 30, 2020
Finite-lived Intangible Assets
Amortization of intangible assets beginning balance	$ 4,261	$ 2,883
Amortization	(1,768)	(703)
Amortization of intangible assets ending balance	24,233	4,261
Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		2,081
HistoTox Labs
Finite-lived Intangible Assets
Acquisition	8,500
Bolder BioPATH
Finite-lived Intangible Assets
Acquisition	12,500
BioReliance Corporation
Finite-lived Intangible Assets
Acquisition	640
Gateway Pharmacology Laboratories LLC
Finite-lived Intangible Assets
Acquisition	100
Trademarks
Finite-lived Intangible Assets
Amortization of intangible assets beginning balance	1,429	1,072
Amortization	(109)	(103)
Amortization of intangible assets ending balance	1,320	1,429
Trademarks \| Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		460
Client Relationships
Finite-lived Intangible Assets
Amortization of intangible assets beginning balance	2,570	1,670
Amortization	(1,413)	(380)
Amortization of intangible assets ending balance	21,197	2,570
Client Relationships \| Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		1,280
Client Relationships \| HistoTox Labs
Finite-lived Intangible Assets
Acquisition	6,800
Client Relationships \| Bolder BioPATH
Finite-lived Intangible Assets
Acquisition	12,500
Client Relationships \| BioReliance Corporation
Finite-lived Intangible Assets
Acquisition	640
Client Relationships \| Gateway Pharmacology Laboratories LLC
Finite-lived Intangible Assets
Acquisition	100
Non-Compete Agreements
Finite-lived Intangible Assets
Amortization of intangible assets beginning balance	258	131
Amortization	(244)	(93)
Amortization of intangible assets ending balance	1,714	258
Non-Compete Agreements \| Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		220
Non-Compete Agreements \| HistoTox Labs
Finite-lived Intangible Assets
Acquisition	1,700
Backlog
Finite-lived Intangible Assets
Amortization		(121)
Backlog \| Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		121
Patents
Finite-lived Intangible Assets
Amortization of intangible assets beginning balance	4	10
Amortization	(2)	(6)
Amortization of intangible assets ending balance	2	4
Patents \| Pre-Clinical Research Services, Inc.
Finite-lived Intangible Assets
Acquisition		$ 0
Patents \| HistoTox Labs
Finite-lived Intangible Assets
Acquisition	0
Patents \| Bolder BioPATH
Finite-lived Intangible Assets
Acquisition	0
Patents \| BioReliance Corporation
Finite-lived Intangible Assets
Acquisition	0
Patents \| Gateway Pharmacology Laboratories LLC
Finite-lived Intangible Assets
Acquisition	$ 0

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsRollForward
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_PreClinicalResearchServicesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_HistotoxLabsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_BolderBioPTHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_BioRelianceCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_GatewayPharmacologyLaboratoriesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=notv_ClientRelationshipsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OrderOrProductionBacklogMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: